Elekta also made news in April, when Proton Partners International Ltd. agreed to buy and install its MR-linac system at a network of cancer centers under development in the U.K.

The British healthcare enterprise plans to acquire five systems for an order value of £25 million ($34,915,950). Installation of all five is expected to take place over a period of three years.


In March, the company paired with IBM to set out to bridge inconsistent care gaps in cancer care globally, through a partnership combining Elekta’s MOSAIQ Oncology Information System and IBM’s Watson for Oncology platform.

The move underscored the company effort to place radiotherapy and oncology treatment in developing nations on the same level as those in high-end markets, such as the U.S. and countries in Western Europe.

“If we look at all cancers in terms of effective treatment and five-year survival, in a high market like the U.S. or Western Europe, we’re expecting about a fifty percent survival rate,” Andrew Wilson, vice president of Elekta’s global marketing digital portfolio, said at the time. "Standardization of oncology care means closing the oncology treatment gap for all ... But if you look at different countries with lower GDP, these are when co-statistics start to drop, and in some articulate disease areas it’s very evident of the inequality that exists across different markets.”

Back to HCB News

Rad Oncology Homepage